☀️ Excessive Daytime Sleepiness Epworth Scale Simulator

Untreated Narcolepsy — Severe Excessive Daytime Sleepiness

Narcolepsy drives dozing in nearly every daily situation, untreated.

• 18-24: Typical untreated Epworth (severe range)
• ~1 in 2,000: Narcolepsy prevalence (US population)
• >90%: Orexin neuron loss (type 1 narcolepsy)
• ~8-10: Years to diagnosis (average delay)

What the Epworth scale measures

Eight everyday situations rated 0-3 for dozing chance.

Why narcolepsy scores so high

Orexin loss destabilizes wake state control severely.

Impact of untreated severe EDS

Driving, work, and safety risks rise sharply.

Treatment Initiated — Starting a Wake-Promoting Agent

A wake-promoting drug is prescribed and titrated to target dose.

• Modafinil, solriamfetol: First-line agents (wake-promoting class)
• Low, titrated: Typical starting dose (up over 1-2 weeks)
• Days: Onset of any effect (full effect later)
• Nighttime dosing: Oxybate option (consolidates sleep)

Wake-promoting drug classes

Modafinil, solriamfetol, and pitolisant target distinct pathways.

Titration and adherence

Consistent daily dosing drives predictable improvement.

Setting expectations

Score reduction builds gradually over weeks, not days.

Weeks 2-4 — Partial Epworth Score Reduction

Dozing likelihood drops first in passive, low-stimulation situations.

• ~5-8 pt drop: Typical score by week 4 (from baseline)
• TV, reading: Situations improving first (passive settings)
• Weeks 1-4: Dose adjustment window (common titration period)
• Large: Adherence effect (missed doses blunt gains)

Early pharmacologic effect

Steady-state drug levels begin stabilizing wakefulness.

Which items improve first

Passive dozing triggers respond before active ones.

Adherence matters most now

Skipped doses noticeably slow early gains.

Weeks 8-12 — Trending Toward the Normal Range

Sustained dosing pushes the total score closer to normal levels.

• ~9-12: Typical score by week 12 (mild-to-normal range)
• Notable: Driving-item improvement (safety-relevant gain)
• ~10-12 wks: Plateau onset (diminishing returns begin)
• ≤10: Normal Epworth cutoff (general population)

Long-term response pattern

Improvement decelerates as it approaches a plateau.

Residual sleepiness

Some patients retain mild residual EDS despite therapy.

Monitoring during this phase

Repeat Epworth scoring tracks ongoing response.

Meaningful, Sustained Reduction in Daytime Sleepiness

A clinically meaningful Epworth drop reflects real functional gains.

• ~2 pts: Minimal clinically important diff. (established threshold)
• ~40-60%: Responders reaching ≤10 (on monotherapy)
• Common: Combination therapy option (for partial responders)
• Every visit: Ongoing reassessment (Epworth re-scored routinely)

Defining treatment response

A drop of 2+ points is considered clinically meaningful.

Partial vs full responders

Some patients need add-on or combination therapy.

Long-term management

Periodic Epworth rescoring guides dose adjustments.